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Abstract 
Purpose: To understand the influence of wet age-related macular degeneration (AMD), both 
treated with anti-VEGF and not treated, in geographic atrophy (GA) progression in the fellow eye 
and to verify if the GA baseline area can also be a risk factor. 
Methods: We accessed retrospectively data from Fundus Autofluorescence (FAF) of patients 
with GA and we measured GA area through images collected in different visits. We defined 3 
groups of patients: group 1 with GA and without wet AMD; group 2 with GA and concomitant 
wet AMD with a disciform scar; and group 3 with GA and wet AMD treated with anti-VEGF in 
the fellow eye. We compared differences of GA area progression between these three groups. 
Finally, we selected patients that had 3 or more images and we compared GA progression between 
the first and the last intervals of the measurements. 
Results: The overall mean of GA area progression rate in the 3 groups was of 1.1±1.1; 0.7±0.6 
and 1.2±1.1 mm2/year, respectively. Comparing the groups together there was no statistically 
significant difference: group 1 and 2 (p=0.225); group 1 and 3 (p=0.918); group 2 and 3 (p=0.309). 
The mean of the GA area progression rate relative to the first and the last interval was of 1.17±1.3 
and 0.79±0.9 mm2/year, respectively (p=0.095).  
Conclusion: We found no association of GA progression rate with either the presence of 
treated or not treated wet AMD in the fellow eye and the baseline area of GA. 
 
 
 
 
 
 
 
 
Introduction 
Age-related macular degeneration (AMD) is a common chorioretinal degenerative condition 
and a main cause of blindness in elderly population, especially in developed countries (Nowak 
2006, Fraser-Bell, Choudhury et al. 2010, Ambati and Fowler 2012, Sigler and Randolph 2013). 
There are some risk factors that are associated with the development of AMD, including soft 
drusen, genetic factors and smoking. On the other hand, nutritional supplements, on the basis of 
vitamin complexes, appear to slow the progression of late AMD (Age-Related Eye Disease Study 
Research 2001, Age-Related Eye Disease Study 2 Research, Chew et al. 2014). Therefore, its 
pathogenesis is likely due to the interaction of metabolic, functional, genetic and environmental 
factors (Nowak 2006, Sigler and Randolph 2013). 
Two subgroups of AMD are classically distinguished: atrophic (dry form) and exudative (wet 
form). Dry AMD is a chronic disease that may cause some degree of visual impairment and 
sometimes progresses to severe blindness. On the other hand, wet AMD affects about 10-15% of 
AMD patients, emerges abruptly and rapidly progresses to blindness if left untreated (Wong, 
Chakravarthy et al. 2008, Ambati and Fowler 2012, Bhutto and Lutty 2012). A considerable 
number of patients develop wet AMD form on a background of dry AMD. Thus, some authors 
think that dry AMD can be a precursor state for wet AMD (Bhutto and Lutty 2012, Grunwald, 
Daniel et al. 2014, Schutze, Wedl et al. 2015).  
Geographic atrophy (GA) represents the late stage manifestation of dry AMD, and it is 
characterized by a progressing course leading to degeneration of retinal pigment epithelium (RPE) 
and photoreceptors, which rely on the RPE for trophic support (Nowak 2006, Gobel, Fleckenstein 
et al. 2011, Ambati and Fowler 2012). Some etiologic mechanisms contribute to the development 
of GA and include senescence, ischemia, oxidative and photo-oxidative damage, inflammation, 
and improper RNA processing (Zarbin 2004, Kaneko, Dridi et al. 2011, Kumar, Mrejen et al. 
2013). Atrophic areas enlarge continuously over time and are associated with a corresponding 
absolute scotoma. The extent of the foveal involvement determines visual acuity (VA) (Joussen 
and Bornfeld 2009, Gobel, Fleckenstein et al. 2011). Some risk factors promote the GA 
progression and they include hyperautofluorescence detected on the surrounding area of GA 
(Bearelly, Khanifar et al. 2011, Batioglu, Gedik Oguz et al. 2014), the pattern configurations and 
the number of GA regions (Sunness, Margalit et al. 2007). Furthermore, larger lesions appear to 
manifest higher growth rates, compared to smaller ones (Csaky, Richman et al. 2008, Biarnes, 
Arias et al. 2015). Smoking or body mass index do not appear to confer additional risk (Lindblad, 
Lloyd et al. 2009). There is to date no means of treatment to counteract or slow the progression 
of GA, contrary to wet AMD (Nowak 2006, Ambati and Fowler 2012, Kanagasingam, Bhuiyan 
et al. 2014). 
Fundus Autofluorescence (FAF) represents a non-invasive imaging modality that allows for 
accurate identification, quantification and segmentation of atrophic areas and currently represents 
the gold standard for evaluating progressive GA enlargement (Gobel, Fleckenstein et al. 2011). 
This method allows topographic mapping of lipofuscin in RPE and because in eyes with GA the 
atrophic areas have deficit of lipofuscin, they correspond to hypofluorescent dark areas 
(Fleckenstein, Charbel Issa et al. 2008). 
On the other hand, the late stage of wet AMD is choroidal neovascularization (CNV). It is 
characterized by the growth of abnormal blood vessels from the choroid underneath the macula, 
haemorrhage and, in untreated patients, the final stage of this disorder is a disciform scar. This 
was thought to be a stable lesion. However, a study presented some cases of patients with 
disciform scars in which a ring of atrophy developed and extended around the scar (Sarks, Tang 
et al. 2006). In fact, the proposed etiologic stimuli for the development of CNV are similar as for 
GA and include ischemia, senescence, oxidative and photo-oxidative damage, and inflammation 
(Spaide, Armstrong et al. 2003, Zarbin 2004, Scholl, Fleckenstein et al. 2007). The 
overexpression of vascular endothelial growth factor (VEGF) is considered to be the cause of 
CNV and utility of anti-VEGF intravitreal therapy is well established in the treatment of CNV 
associated with AMD. Many studies have shown that ranibizumab, aflibercept and bevacizumab 
improve the visual acuity (Joussen and Bornfeld 2009, Amaro and Roller 2012, Jaffe, Martin et 
al. 2013, Grunwald, Daniel et al. 2014). However, macular morphological responses after anti-
VEGF therapy are quite varied. One of the findings observed in some studies is the development 
of RPE and choriocapillary atrophy that suggests the appearance of de novo GA or, more 
frequently, faster progression of GA area in the eye submitted to treatment (Jaffe, Martin et al. 
2013, Grunwald, Daniel et al. 2014, Schutze, Wedl et al. 2015). 
Our study aims to understand whether the presence of wet AMD simultaneously with GA 
influences the progression rate of GA and to verify if the treatment with anti-VEGF in wet AMD 
has any effect on the rate of GA progression. This association has been proven within the treated 
eye (Grunwald, Daniel et al. 2014, Schutze, Wedl et al. 2015) and we will analyse that possible 
relation in the fellow eye. We will also try to comprehend the influence of the baseline GA area 
in GA area progression. 
 
Methods  
In this retrospective study we defined 3 groups of patients: group 1 with GA and without wet 
AMD; group 2 with GA and concomitant wet AMD that was not treated in the fellow eye due to 
a disciform scar; and group 3 composed of patients with GA and wet AMD treated with anti-
VEGF in the fellow eye. The study was approved by the ethics committee of Centro Hospitalar 
São João. 
To obtain the information of the presence of concomitant wet AMD and GA and also to know 
if the patient is being treated with anti-VEGF therapy for wet AMD, we accessed the medical 
records. In patients that were being treated for wet AMD in the fellow eye, the number of 
injections per year and the drug used was also collected. All patients were imaged using the 
Spectralis® Heidelberg® SLO-OCT. Only FAF images with sufficient quality to be assessed 
using the Region Finder® software of the Spectralis® Heidelberg® were included in this study.  
Patients were selected from the Spectralis® Heidelberg® database of the SLO-OCT machine 
of the Centro Hospitalar São João by selecting the diagnosis “geographic atrophy”. To be included 
in the study the patients must have at least 2 funds autofluorescence images, and 1 year of follow 
up. In patients with several images each year, the images were graded with at least one year apart. 
We also defined the following exclusion criteria: area of GA larger than the window obtained 
from the Spectralis® AF image and the presence of other retinal disease such as diabetic 
retinopathy. For each patient included, baseline in this study was defined as the first 
autofluorescence image obtained, that could be either when GA (group 1) or wet AMD (group 2) 
was diagnosed in the fellow eye or after treatment started for this last disorder. The end of the 
follow up was considered to be the date of the last autofluorescence image. 
We used data from patients that are being followed in the Retina Department of Hospital de 
São João. Here, patients with GA are followed through two non-invasive imaging modalities: 
FAF and Spectral-domain optical coherence tomography (SD-OCT), using the Spectralis® 
Heidelberg®. In routine clinical practice, clinicians recorded images with these two techniques. 
We used Heidelberg SPECTRALIS® Software to retrospectively access data from FAF modality.  
To measure the GA area in each patient we accessed images recorded before, in medical 
appointments, and we outlined the area with the mouse-driven cursor using the Region FinderTM 
(Heidelberg Engineering) software. Briefly, the Region Finder software identifies areas of similar 
fluorescent intensity in one retinal image that is a square of 20º. One operator manually selects 
the areas of interest to be measured. The software then automatically calculates the size of the 
areas of interest. When the same eye is re-measured on a latter image, the software calculates the 
differences in the size of the marked areas and automatically calculates the area change and 
respective growth rates. 
For this study, in patients with bilateral Geographic Atrophy we arbitrarily selected the right 
eye to perform the analysis. In patients with more than two measurements, the sequential growth 
rates were calculated over time to understand if longstanding disease also affected progression of 
Geographic Atrophy or if continuous anti-VEGF treatment increased growth rates. 
To analyse data obtained during the study we used IBM-SPSS software version 23.0 (IBM-
SPSS, Inc, Chicago, IL) and we performed frequency and descriptive statistics. In all tests we 
considered statistical significance if P<0.05. We calculated statistically significant differences of 
GA progression between the three groups related to the presence of wet AMD defined above. For 
that purpose we used Student’s t-test. Finally, we selected patients that had 3 or more 
measurements of GA area and we compared GA progression between the first and the last 
intervals of the measurements. To perform that statistical analysis we used paired sample t-test. 
Results 
Initially, 86 patients were collected from the data base and 58 of these were included. Of the 
28 patients excluded, 18 (64%) did not have enough images to perform the analysis, lesions were 
larger than window size in 6 patients (21%), other ophthalmologic lesions were detected in 3 
patients (11%) and 1 (4%) had no evidence of GA lesions. 
Of the 58 accepted eyes, 35 (60%) patients had GA without AMD; 11 (19%) had wet AMD 
not treated in the fellow eye and 12 (21%) had wet AMD treated with anti-VEGF in the fellow 
eye (Table 1). 23 (40%) were male patients and 35 (60%) were female.  
The mean age of the patients was 82±6 years. Taking into account each group individually, 
the mean age from patients with GA without wet AMD was of 82±7 years, from patients with wet 
AMD not treated in the fellow eye was of 84±4 years and from patients with wet AMD treated 
with anti-VEGF in the fellow eye was of 81±7 years (Table 1). Comparing the groups, there was 
no statistically significant difference between group 1 and 2, group 1 and 3, and between group 2 
and 3 (p=0,361; p=0,665; p=0,230, Student’s t-test). 
Regarding to the measurements performed, 6 patients (10%) had two measurements included, 
10 (17%) had 3 and 42 patients (73%) had four, resulting in a mean of 3.6 images per eye. The 
mean period of follow up was 35±14 months.  
In relation to patients with wet AMD treated with anti-VEGF in the fellow eye, 8 of them 
(67%) were treated with bevacizumab, while 4 (33%) were treated with ranibizumab (Table 1). 
Patients initially treated with ranibizumab were eventually switched to bevacizumab due to 
hospital policy. No patients were treated with aflibercept. The mean number of injections 
performed was of 5 per patient per year.  
The mean time of follow up was 35±14 months. Attending to the GA area at the first image, 
the mean was of 3.8±5.1 mm2 and at the last was of 6.6±7.0mm2. Once more, particularizing to 
each group, the initial GA area of the groups 1, 2 and 3 was of 4.2±5.9 mm2, 4.4±3.9 mm2 and 
2.2±2.8 mm2, respectively (Table 2). Comparing the GA area at the first image between groups 1 
and 2, there was no statistically significant difference (p=0,918, Student’s t-test). The relation was 
not statistically significant as well between group 1 vs group 3 and group 2 vs group 3 (p=0,264; 
p=0,128, Student’s t-test).  
Data concerning GA area progression rate between the images collected at different times 
during the study in all the 3 groups are shown at Table 2. In the first interval between 
measurements, the GA area progression rate for group 1 was of 1.3±1.5 mm2/year, for group 2 
1.5±1.5mm2/year and for group 3 1.3±1.1 mm2/year. The same variable studied for the last 
interval, in patients with more than 3 measurements performed, was of 0.9±0.9 mm2/year for 
group 1, 0.5±0.9 mm2/year for group 2 and 0.8±0.8 mm2/year. In relation to the overall mean of 
GA area progression rate (between the first and the last image obtained – overall period), in group 
1 it was 1.1±1.1 mm2/year, in group 2 it was 0.7±0.6 mm2/year and in group 3, 1.2±1.1 mm2/year. 
The relation between GA area progression rate between the patients with GA without wet AMD 
in the fellow eye and patients with wet AMD not treated in the fellow eye was not statistically 
significant, both in the first and last the interval and even in the overall period (p=0,701; p=0.195; 
p=0.225, respectively, Student’s t-test). Comparing patients with GA without wet AMD and 
patients with wet AMD treated with anti-VEGF in the fellow eye, the relation was not statistically 
significant as well in the same 3 different intervals defined above (p=0.954, first interval; p=0.660, 
last interval; p=0.918, overall period; Student’s t-test). Furthermore, there was no statistically 
significant difference between patients with wet AMD not treated and the ones treated with anti-
VEGF (p=0.673, first interval; p=0,434, last interval; p=0.309, overall period; Student’s t-test).  
Regarding to the comparison of the GA area progression rate between the first and the last 
interval of the measurements, there was no statistically significant difference (p=0.095, paired 
sample t-test). The mean of the GA area progression rate of the first interval was of 1.17±1.3 
mm2/year while the mean of the last interval was of 0.79±0.9 mm2/year. The mean time between 
the two measurements in the first interval was 12±6 months and in the last interval was 15±7 
months. 
 
Discussion 
As mentioned above, several studies implicated the development of GA through various 
mechanisms and risk factors (Fraser-Bell, Choudhury et al. 2010, Ambati and Fowler 2012, 
Danis, Lavine et al. 2015).  
In fact, in the past, the association between GA and wet AMD was not a focus of clinical 
interest. However, since the development of the most recent pharmacologic therapeutic for wet 
AMD with anti-VEGF agents that blocked neovascularization process, the affected eyes no longer 
progress to bleeding and fluid leakage. Instead, they start to develop gradual loss of RPE cells 
that lead to further vision loss. Therefore, this started to be an increasingly studied area (Danis, 
Lavine et al. 2015). 
Of particular interest, a prospective study showed that the progression of GA area is 
significantly higher in patients that are being treated with anti-VEGF medication for the CNV 
developed in the same eye (Grunwald, Daniel et al. 2014).  
A retrospective study analysed the same outcome and found that areas of GA have developed 
at the place of previous neovascular lesion in patients with CNV treated with anti-VEGF and 
these areas enlarged over time. However, patients submitted to anti-VEGF treatment do not 
appear to develop GA in eyes without AMD.  (Tanaka, Chaikitmongkol et al. 2015).  
In fact, both of GA and CNV may develop in the same eye and the risk factors for the 
development of both are indistinguishable. Therefore neovascular process causes a set of changes 
at the cellular level that leads to progressive stress and GA may develop de novo or, most likely, 
pre-existing GA may continue to worsen (Grunwald, Daniel et al. 2014, Danis, Lavine et al. 
2015).  
We performed this study trying to understand if this processes explained above occur in the 
fellow eye. Patients with GA were compared with patients with wet AMD not treated with anti-
VEGF. However no association has been found between GA progression and the presence of wet 
AMD in the fellow eye. We also analysed the possible influence of anti-VEGF in the development 
of GA but once more, no difference has been found between patients with wet AMD in the fellow 
eye treated with anti-VEGF and patients that had GA exclusively. There were no differences 
between the two groups of patients with wet AMD (treated and not treated with anti-VEGF).  
Therefore treatment with anti-VEGF does not seem to influence the progression rate of 
geographic atrophy in the fellow eye, but physicians must have caution in doses applied of that 
medication because of the adverse effects that other studies have shown in the same eye (Kumar, 
Mrejen et al. 2013, Grunwald, Daniel et al. 2014, Schutze, Wedl et al. 2015, Tanaka, 
Chaikitmongkol et al. 2015). Even though there is data that supports the progression of geographic 
atrophy in the treated eye, in our study, no effect was found in the untreated eye, showing that the 
eventual systemic exposure in the doses used is irrelevant for the progression of this disease. In 
fact, taking into account the two anti-VEGF agents used in our study, bevacizumab seems to have 
increased systemic absorption, compared to Ranibizumab (Carneiro, Costa et al. 2012). Since 
most of the patients were treated with bevacizumab (even patients who were initially treated with 
ranibizumab, switched to bevacizumab in the last administrations) and there were no statistically 
significant differences regarding the GA progression comparing to the other groups of the study, 
ranibizumab would not theoretically show a different effect. Further studies with more patients 
are needed to understand the real effect of these two drugs. 
Furthermore, a recent study suggested that one of the most prominent known drivers of GA 
growth is the baseline GA area and that enlargement of the area induces changes in FAF, with 
larger lesion areas leading to subsequent higher growth rates (Biarnes, Arias et al. 2015). This is 
against other proposed hypothesis, where elevated intracellular lipofuscin cause high levels of 
FAF, with consequent death of RPE cells and GA area progression (Biarnes, Arias et al. 2015). 
We compared GA area progression rate between the first and the last intervals of 
measurements in patients with at least 3 images obtained, trying to understand if the growth of 
GA area would be faster in patients with progressively higher areas, that is, in last interval. We 
also compared this in the different groups to determine if repeated intravitreal anti-VEGF agents 
had long term effects on the rate of geographic atrophy growth of the fellow eye. We found no 
differences of GA area progression rate between the two intervals, so we cannot assume in this 
case that the initial size of GA had any influence on GA progression. Also, repeated anti-VEGF 
exposure of the fellow eye did not affect the growth rate of the fellow eye. However, further 
studies are needed to elucidate this hypothesis, particularly with longer follow up time and 
analysing other important characteristics like FAF patterns and the influence of lipofuscin, 
namely its distribution.   
Beyond its retrospective nature, our study had other important limitations. We did not have 
access to smoking history and anti-oxidant intake, what could be necessary to control biases. We 
also did not obtain images through SD-OCT modality. For that reason, it was not possible for us 
to evaluate anatomic characteristics and its relationship with the FAF images, what may provide 
us important information. 
In conclusion, our study found no association of Geographic Atrophy area progression rate 
with either the presence of treated or not treated wet AMD in the fellow eye and the baseline area 
of Geographic Atrophy. Nevertheless it is important to take into account that it has been shown 
that antiangiogenic therapy in patients with wet AMD may promote GA progression with 
subsequent macular atrophy and visual impairment in this population (Biarnes, Arias et al. 2015). 
Although these events occur mainly in the treated eye, further studies with more patients will be 
able to evaluate the variables mentioned above and will yield further conclusions. 
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Tables 
 
Table 1 
 
 GA Wet AMD disciform scar Wet AMD treated 
Eyes (n) 35 11 12 
Gender 18F 17M 9F 2M 8F 4M 
Mean Age (years)* 82±7 84±4 81±7 
anti-VEGF - - 8 Bev 4 Ran 
 
Table 1: Baseline Characteristics: Number of eyes, gender, mean age and anti-VEGF used in patients with 
treated wet AMD, according to the groups of patients defined in our study. AMD: age-related macular 
degeneration; Bev: bevacizumab; F: female; GA: geographic atrophy; M:  male; Ran: ranibizumab. *The 
differences in the mean age were not statistically significant between the three groups. 
 
 
Table 2 
 
 GA Wet AMD disciform scar Wet AMD treated 
Baseline GAAa 
(mm2) 
4.2±5.9 4.4±3.9 2.2±2.8 
Mean of overall 
GAA progression 
rateb (mm2/year) 
1.1±1.1 0.7±0.6 1.2±1.1 
GAA progression 
rate in the first 
intervalc (mm2/year) 
1.3±1.5 1.5±1.5 1.3±1.1 
GAA progression 
rate in the last 
intervalc (mm2/year) 
0.9±0.9 0.5±0.9 0.8±0.8 
 
Table 2: Area of Geographic Atrophy at the first image and the GAA progression rate in different intervals 
among the images obtained, according to the groups of patients defined in our study. AMD: age-related 
macular degeneration; GA: geographic atrophy; GAA: geographic atrophy area. aThere was no statistically 
significant difference between the three groups in relation to the baseline GAA. bThe differences in the 
mean of overall GAA progression rate between the three groups were not statistically significant. cThere 
was no statistically significant difference comparing GA area progression rate between the first and the last 
interval. 
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